Formulation Development
Catalent Completes Acquisition of Gene Therapy Leader for $1.2 Billion
Catalent, Inc. recently announced it has completed the $1.2-billion acquisition of Paragon Bioservices, Inc., a leading viral vector development and manufacturing partner for gene therapies.…
CureVac Enters Into Exclusive Sponsored Research Agreement
CureVac AG, a fully integrated biopharmaceutical company pioneering the field of mRNA-based drugs, recently announced it has entered into a sponsored research agreement (SRA) with…
Crinetics Pharmaceuticals Initiates Phase 1 Study for Treatment of Neuroendocrine Tumors
Crinetics Pharmaceuticals, Inc. recently announced the initiation of a Phase 1, double-blind, randomized, placebo-controlled, single- and multiple-dose study to evaluate the safety, pharmacokinetics, and pharmacodynamics…
BioCryst’s Oral Drug Meets Primary Endpoint in Phase 3
BioCryst Pharmaceuticals, Inc. recently announced that the randomized (n=121), double-blind, placebo-controlled, Phase 3 APeX-2 trial of once-daily, oral BCX7353 for the prevention of hereditary angioedema…
WuXi STA & Dizal Pharmaceutical Sign Agreement
STA Pharmaceutical Co., Ltd., (WuXi STA) – a subsidiary of WuXi AppTec – and Dizal Pharmaceutical, a biotechnology company, recently announced a strategic partnership.
Mercia Invests in Transdermal Drug Delivery Specialist
Medherant Limited, the clinical-stage developer of innovative transdermal delivery products for pain and CNS diseases using its unique TEPI Patch technology, recently announced a new $2.5-million investment.
Catalent to Launch OneBio Suite for Integrated Biologics Development, Manufacturing & Supply
Catalent (Booth 3101) recently announced it will launch its new OneBio Suite for the integrated development, manufacturing, and clinical supply of biologic drugs at the…
Yamo Pharmaceuticals Presents Results from Phase 2 Study
Yamo Pharmaceuticals, LLC recently announced the presentation of results from a Phase 2 study with L1-79 in the treatment of ASD. A poster, titled An…
Elligo Health Research Launches Novel IntElligo Research Stack Clinical Technology
Elligo Health Research recently announced the launch of its innovative IntElligo Research Stack clinical technology. This standards-based technology platform, which powers the System of Accelerated…
ProBioGen & Vaccitech Sign License Agreement
ProBioGen AG and Vaccitech, Ltd. jointly announced signing a license agreement in which Vaccitech will gain access to ProBioGen’s proprietary technology platform based on the…
Codexis Announces CodeEvolver Technology Transfer & License Agreement With Global Pharmaceutical Leader
Codexis, Inc. recently announced the signing of a CodeEvolver platform agreement with Novartis. Under the terms of the agreement, Codexis has granted a non-exclusive license…
Adaptimmune & Alpine Immune Sciences Announce Collaboration & License Agreement
Adaptimmune Therapeutics plc and Alpine Immune Sciences, Inc. recently announced a collaboration and license agreement to develop next-generation SPEAR T-cell products that incorporate Alpine’s secreted…
Cybrexa Therapeutics’ alphalex Platform Enables Tumor Targeting of Multiple PARP Inhibitors
Cybrexa Therapeutics recently announced preclinical data supporting the potential of its proprietary alphalex technology platform.
Caris Life Sciences Receives FDA Breakthrough Device Designation
Caris Life Sciences recently announced the US FDA has granted Breakthrough Device designation for the company’s MI Transcriptome companion diagnostic (CDx) test. Designed to detect…
Merus Announces First Patient Treated in Phase 1 Clinical Trial for Advanced Solid Tumors
Merus N.V. recently announced the first patient has been treated in its Phase 1 trial evaluating safety, tolerability, and preliminary efficacy of MCLA-145 for the…
Chinese Patent Office Issues Notice of Acceptance for Multiwavelength PhotoDynamic Therapy
Theralase Technologies Inc., a clinical stage pharmaceutical company dedicated to the research and development of light activated PhotoDynamic Compounds (PDCs) and their associated drug formulations…
Sarepta Announces Agreement With Nationwide Children’s Hospital for Rights to its Gene Therapy Program
Sarepta Therapeutics, Inc. recently announced it has recently signed an agreement with the Research Institute at Nationwide Children’s Hospital (Nationwide Children’s) giving Sarepta the exclusive…
Octapharma Study Demonstrates Cutaquig Efficacy & Safety
Octapharma presented clinical research results at the Clinical Immunology Society Annual Meeting in Atlanta demonstrating the efficacy and safety of cutaquig [Immune Globulin Subcutaneous (Human)…
Merck Announces Results from Phase 2 Trial
Merck recently announced results from a Phase 2 trial (NCT02982972) evaluating the safety, tolerability, and immunogenicity of V114, the company’s investigational 15-valent pneumococcal conjugate vaccine,…
HOOKIPA Achieves Research Milestone in Collaboration & License Agreement With Gilead
HOOKIPA Pharma Inc. recently announced it has achieved a further research milestone in its collaboration and license agreement with Gilead Sciences, Inc. for development of a therapeutic hepatitis B virus (HBV) vaccine.
